Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC Bio-PathRetainsInvestmentBankingFirmMaximGroupLLC
Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results PR_BPTH_Second_Quarter_2013_Earnings_Release
Bio-Path Holdings’ Liposomal Delivery Technology Achieves Major Milestone in development of Antisense Therapeutics Bio_Path_Delivery_Technology_Major_Milestone
Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers Testing_initiated_in_TNBC_IBC
Bio-Path Holdings Successfully Completes Fifty Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia PR_Fifth_Cohort_Complete_June_2013
Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results PR_bpth_First_Qtr_2013_Earnings_Release
Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results PR_2012_Earnings_Release
Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias PR_Fifth_Cohort20130307
Bio-Path Holdings to Present at Biotech Showcase 2013 Conference in San Francisco, California on Tuesday, January 8, 2013 at 11:00 am Pacific Time PR_Presentation_at_Biotech_Showcase_2013_Conference
Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two additional indications: Triple Negative and Inflammatory Breast Cancers Development_of_Liposoma_Grb-2_for_TNBC_and_IBC_final_12_6_12
